News | March 14, 2023
Pfizer acquires Seagen for US$ 43 billion to battle cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Proposed combination enhances Pfizer’s position as a leading company in oncology
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Subscribe To Our Newsletter & Stay Updated
